These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 30355675)

  • 1. Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer.
    Basudan A; Priedigkeit N; Hartmaier RJ; Sokol ES; Bahreini A; Watters RJ; Boisen MM; Bhargava R; Weiss KR; Karsten MM; Denkert C; Blohmer JU; Leone JP; Hamilton RL; Brufsky AM; Elishaev E; Lucas PC; Lee AV; Oesterreich S
    Mol Cancer Res; 2019 Feb; 17(2):457-468. PubMed ID: 30355675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma.
    Cao L; Basudan A; Sikora MJ; Bahreini A; Tasdemir N; Levine KM; Jankowitz RC; McAuliffe PF; Dabbs D; Haupt S; Haupt Y; Lucas PC; Lee AV; Oesterreich S; Atkinson JM
    Cancer Lett; 2019 Oct; 461():21-30. PubMed ID: 31229512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.
    Hartmaier RJ; Trabucco SE; Priedigkeit N; Chung JH; Parachoniak CA; Vanden Borre P; Morley S; Rosenzweig M; Gay LM; Goldberg ME; Suh J; Ali SM; Ross J; Leyland-Jones B; Young B; Williams C; Park B; Tsai M; Haley B; Peguero J; Callahan RD; Sachelarie I; Cho J; Atkinson JM; Bahreini A; Nagle AM; Puhalla SL; Watters RJ; Erdogan-Yildirim Z; Cao L; Oesterreich S; Mathew A; Lucas PC; Davidson NE; Brufsky AM; Frampton GM; Stephens PJ; Chmielecki J; Lee AV
    Ann Oncol; 2018 Apr; 29(4):872-880. PubMed ID: 29360925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK4/6 Inhibitor Efficacy in
    Lloyd MR; Brett JO; Carmeli A; Weipert CM; Zhang N; Yu J; Bucheit L; Medford AJ; Wagle N; Bardia A; Wander SA
    NEJM Evid; 2024 May; 3(5):EVIDoa2300231. PubMed ID: 38815172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers.
    Fumagalli D; Wilson TR; Salgado R; Lu X; Yu J; O'Brien C; Walter K; Huw LY; Criscitiello C; Laios I; Jose V; Brown DN; Rothé F; Maetens M; Zardavas D; Savas P; Larsimont D; Piccart-Gebhart MJ; Michiels S; Lackner MR; Sotiriou C; Loi S
    Ann Oncol; 2016 Oct; 27(10):1860-6. PubMed ID: 27672107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver tropism of ER mutant breast cancer is characterized by unique molecular changes and immune infiltration.
    Wu Y; Li Z; Lee AV; Oesterreich S; Luo B
    Breast Cancer Res Treat; 2024 Jun; 205(2):371-386. PubMed ID: 38427312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.
    Chu D; Paoletti C; Gersch C; VanDenBerg DA; Zabransky DJ; Cochran RL; Wong HY; Toro PV; Cidado J; Croessmann S; Erlanger B; Cravero K; Kyker-Snowman K; Button B; Parsons HA; Dalton WB; Gillani R; Medford A; Aung K; Tokudome N; Chinnaiyan AM; Schott A; Robinson D; Jacks KS; Lauring J; Hurley PJ; Hayes DF; Rae JM; Park BH
    Clin Cancer Res; 2016 Feb; 22(4):993-9. PubMed ID: 26261103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
    Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
    Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.
    Priedigkeit N; Hartmaier RJ; Chen Y; Vareslija D; Basudan A; Watters RJ; Thomas R; Leone JP; Lucas PC; Bhargava R; Hamilton RL; Chmielecki J; Puhalla SL; Davidson NE; Oesterreich S; Brufsky AM; Young L; Lee AV
    JAMA Oncol; 2017 May; 3(5):666-671. PubMed ID: 27926948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
    Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
    Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted mutation detection in breast cancer using MammaSeq™.
    Smith NG; Gyanchandani R; Shah OS; Gurda GT; Lucas PC; Hartmaier RJ; Brufsky AM; Puhalla S; Bahreini A; Kota K; Wald AI; Nikiforov YE; Nikiforova MN; Oesterreich S; Lee AV
    Breast Cancer Res; 2019 Feb; 21(1):22. PubMed ID: 30736836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.
    Wang P; Bahreini A; Gyanchandani R; Lucas PC; Hartmaier RJ; Watters RJ; Jonnalagadda AR; Trejo Bittar HE; Berg A; Hamilton RL; Kurland BF; Weiss KR; Mathew A; Leone JP; Davidson NE; Nikiforova MN; Brufsky AM; Ambros TF; Stern AM; Puhalla SL; Lee AV; Oesterreich S
    Clin Cancer Res; 2016 Mar; 22(5):1130-7. PubMed ID: 26500237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study.
    Moelans CB; Monsuur HN; de Pinth JH; Radersma RD; de Weger RA; van Diest PJ
    Anal Cell Pathol (Amst); 2010; 33(1):13-8. PubMed ID: 20966540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ESR1 amplification in breast cancer by optimized RNase FISH: frequent but low-level and heterogeneous.
    Moelans CB; Holst F; Hellwinkel O; Simon R; van Diest PJ
    PLoS One; 2013; 8(12):e84189. PubMed ID: 24367641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of resistance to estrogen receptor modulators in ER+/HER2- advanced breast cancer.
    Zhang J; Wang Q; Wang Q; Cao J; Sun J; Zhu Z
    Cell Mol Life Sci; 2020 Feb; 77(4):559-572. PubMed ID: 31471681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DC-SCRIPT is a novel regulator of the tumor suppressor gene CDKN2B and induces cell cycle arrest in ERα-positive breast cancer cells.
    Ansems M; Søndergaard JN; Sieuwerts AM; Looman MW; Smid M; de Graaf AM; de Weerd V; Zuidscherwoude M; Foekens JA; Martens JW; Adema GJ
    Breast Cancer Res Treat; 2015 Feb; 149(3):693-703. PubMed ID: 25663546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
    Zundelevich A; Dadiani M; Kahana-Edwin S; Itay A; Sella T; Gadot M; Cesarkas K; Farage-Barhom S; Saar EG; Eyal E; Kol N; Pavlovski A; Balint-Lahat N; Dick-Necula D; Barshack I; Kaufman B; Gal-Yam EN
    Breast Cancer Res; 2020 Feb; 22(1):16. PubMed ID: 32014063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of ESR1 gene copy number changes in breast cancer as measured by fluorescence in situ hybridisation.
    Lin CH; Liu JM; Lu YS; Lan C; Lee WC; Kuo KT; Wang CC; Chang DY; Huang CS; Cheng AL
    J Clin Pathol; 2013 Feb; 66(2):140-5. PubMed ID: 23268322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.
    Holst F; Stahl PR; Ruiz C; Hellwinkel O; Jehan Z; Wendland M; Lebeau A; Terracciano L; Al-Kuraya K; Jänicke F; Sauter G; Simon R
    Nat Genet; 2007 May; 39(5):655-60. PubMed ID: 17417639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).
    Pentheroudakis G; Kotoula V; Eleftheraki AG; Tsolaki E; Wirtz RM; Kalogeras KT; Batistatou A; Bobos M; Dimopoulos MA; Timotheadou E; Gogas H; Christodoulou C; Papadopoulou K; Efstratiou I; Scopa CD; Papaspyrou I; Vlachodimitropoulos D; Linardou H; Samantas E; Pectasides D; Pavlidis N; Fountzilas G
    PLoS One; 2013; 8(7):e70634. PubMed ID: 23923010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.